In a Phase IIa clinical trial, 3TC was found to significantly reduce levels of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid of individuals with early Alzheimer's disease, suggestive of reduced neuroinflammation.104. The gene discussed is GFAP; the disease is Alzheimer disease.